Alicia Morgans, MD and Charles Ryan, MD discuss the quality of life between patients with metastatic hormone-sensitive prostate cancer who were treated with ADT+docetaxel and those who were treated with ADT alone.   The importance of the study was to understand how different treatments actually affected the individuals receiving them.

Biographies:

Alicia Morgans, MD, MPH

Charles J. Ryan, MD

Read More:

Quality of Life During Treatment with Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer